Isoform	RefSeq	Entrez Gene ID	Hugo Symbol	Alteration	Protein Change	Cancer Type	Level	Drugs(s)	PMIDs for drug	Abstracts for drug
ENST00000318560	NM_005157.4	25	ABL1	T315I	T315I	B-Lymphoblastic Leukemia/Lymphoma	R1	Nilotinib, Dasatinib, Imatinib, Bosutinib	17768119, 18403620	
ENST00000318560	NM_005157.4	25	ABL1	T315I	T315I	Chronic Myelogenous Leukemia	R1	Nilotinib, Dasatinib, Imatinib, Bosutinib	17768119, 18403620	
ENST00000275493	NM_005228.3	1956	EGFR	Exon 20 insertion	762_823ins	Non-Small Cell Lung Cancer	R1	Erlotinib, Afatinib, Gefitinib	23371856, 24065731, 19536777, 24353160, 21764376, 18676761, 24893891, 23328547, 1867676, 15897572, 17686547	
ENST00000275493	NM_005228.3	1956	EGFR	T790M	T790M	Non-Small Cell Lung Cancer	R1	Afatinib, Erlotinib, Gefitinib	24478319, 26051236, 23816963	Yang et al. Abstract# O03.05, IASLC 2013 http://library.iaslc.org/search-speaker?search_speaker=17991
ENST00000256078	NM_033360.2	3845	KRAS	Oncogenic Mutations	Oncogenic Mutations	Colorectal Cancer	R1	Panitumumab, Cetuximab	21228335, 20619739, 18316791, 20921465, 24024839	
ENST00000369535	NM_002524.4	4893	NRAS	Oncogenic Mutations	Oncogenic Mutations	Colorectal Cancer	R1	Panitumumab, Cetuximab	20619739, 24024844, 25110411, 24024839	
ENST00000257290	NM_006206.4	5156	PDGFRA	D842V	D842V	Gastrointestinal Stromal Tumor	R1	Imatinib	25905001, 17087936, 12949711, 24963404, 22718859, 15928335, 18955458, 23752188, 22745105, 15685537, 18794084	
ENST00000318560	NM_005157.4	25	ABL1	BCR-ABL1 Fusion	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	1	Dasatinib, Imatinib, Ponatinib	17496201, 24180494, 11287973, 24441288, 20131302, 21931113, 12200353	Hunger et al. ASH 2017 http://www.bloodjournal.org/content/130/Suppl_1/98
ENST00000318560	NM_005157.4	25	ABL1	T315I	T315I	B-Lymphoblastic Leukemia/Lymphoma	1	Ponatinib	23044928, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	BCR-ABL1 Fusion	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	1	Nilotinib, Dasatinib, Imatinib, Bosutinib	28095277, 28218239, 27217448, 11287973, 20525993, 29091516, 12637609, 20525995, 23502220, 11287972	
ENST00000318560	NM_005157.4	25	ABL1	T315I	T315I	Chronic Myelogenous Leukemia	1	Ponatinib	24180494, 23190221, 19878872	
ENST00000389048	NM_004304.4	238	ALK	Fusions	Fusions	Non-Small Cell Lung Cancer	1	Crizotinib, Alectinib, Ceritinib	28586279, 29596029, 29668860, 30215676, 28126333, 23724913	
ENST00000389048	NM_004304.4	238	ALK	Oncogenic Mutations	Oncogenic Mutations	Non-Small Cell Lung Cancer	1	Brigatinib, Lorlatinib	30413378, 27432227, 28475456, 29074098, 29768119, 30280657	
ENST00000288602	NM_004333.4	673	BRAF	V600E	V600E	Anaplastic Thyroid Cancer	1	Dabrafenib + Trametinib	29072975	
ENST00000288602	NM_004333.4	673	BRAF	V600	V600	Erdheim-Chester Disease	1	Vemurafenib	26287849, 29188284	
ENST00000288602	NM_004333.4	673	BRAF	V600E	V600E	Melanoma	1	Vemurafenib, Dabrafenib, Dabrafenib + Trametinib, Vemurafenib + Cobimetinib, Trametinib, Encorafenib + Binimetinib	29573941, 22735384, 28961848, 25265494, 25287827, 25399551, 22608338, 23051966, 28891408, 27480103, 22663011, 25265492, 24508103, 29361468, 28991513, 23020132	
ENST00000288602	NM_004333.4	673	BRAF	V600K	V600K	Melanoma	1	Dabrafenib + Trametinib, Vemurafenib + Cobimetinib, Trametinib, Encorafenib + Binimetinib	29573941, 28891408, 27480103, 22663011, 25265492, 25265494, 25287827, 29361468, 28991513, 23020132, 25399551	
ENST00000288602	NM_004333.4	673	BRAF	V600E	V600E	Non-Small Cell Lung Cancer	1	Dabrafenib + Trametinib	27283860, 28919011	
ENST00000357654	NM_007294.3	672	BRCA1	Oncogenic Mutations	Oncogenic Mutations	Ovarian Cancer	1	Rucaparib, Niraparib	27717299, 30425037, 28882436, 28916367, 30948273	
ENST00000357654	NM_007294.3	672	BRCA1	Oncogenic Mutations	Oncogenic Mutations	Peritoneal Serous Carcinoma	1	Rucaparib, Niraparib	27717299, 30425037, 28882436, 28916367, 30948273	
ENST00000380152	NM_000059.3	675	BRCA2	Oncogenic Mutations	Oncogenic Mutations	Ovarian Cancer	1	Rucaparib, Niraparib	27717299, 30425037, 28882436, 28916367, 30948273	
ENST00000380152	NM_000059.3	675	BRCA2	Oncogenic Mutations	Oncogenic Mutations	Peritoneal Serous Carcinoma	1	Rucaparib, Niraparib	27717299, 30425037, 28882436, 28916367, 30948273	
ENST00000275493	NM_005228.3	1956	EGFR	A750P	A750P	Non-Small Cell Lung Cancer	1	Erlotinib, Afatinib, Gefitinib	28336552, 19625781, 25179728, 15737014	
ENST00000275493	NM_005228.3	1956	EGFR	A763_Y764insFQEA	A763_Y764insFQEA	Non-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib	23371856, 24353160, 23969006	
ENST00000275493	NM_005228.3	1956	EGFR	E709K	E709K	Non-Small Cell Lung Cancer	1	Erlotinib, Afatinib, Gefitinib	28336552, 23566546, 18000506, 25179728, 25130612, 23749122, 15710947	
ENST00000275493	NM_005228.3	1956	EGFR	E709_T710delinsD	E709_T710delinsD	Non-Small Cell Lung Cancer	1	Erlotinib, Afatinib, Gefitinib	21531810, 28336552, 26206867	
ENST00000275493	NM_005228.3	1956	EGFR	Exon 19 deletion	729_761del	Non-Small Cell Lung Cancer	1	Erlotinib, Afatinib, Osimertinib, Dacomitinib, Gefitinib	28958502, 23816960, 30659024, 20022809, 21670455, 29151359, 22452895, 25589191, 22285168, 29864379, 19692680, 27987585, 22370314, 20573926	
ENST00000275493	NM_005228.3	1956	EGFR	Exon 19 insertion	729_761ins	Non-Small Cell Lung Cancer	1	Erlotinib, Afatinib, Gefitinib	28336552, 24389445, 25279299, 29340050, 22190593, 21841502, 20075572	
ENST00000275493	NM_005228.3	1956	EGFR	G719	G719	Non-Small Cell Lung Cancer	1	Erlotinib, Afatinib, Gefitinib	21531810, 28336552, 15118073, 26051236, 21670455, 16011858, 24285021, 20573926	
ENST00000275493	NM_005228.3	1956	EGFR	Kinase Domain Duplication	Kinase Domain Duplication	Non-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib	28336552, 26286086	
ENST00000275493	NM_005228.3	1956	EGFR	L747P	L747P	Non-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib	28336552, 22190593	
ENST00000275493	NM_005228.3	1956	EGFR	L833V	L833V	Non-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib	21949883, 23912954, 25130612, 20808254, 21422421	
ENST00000275493	NM_005228.3	1956	EGFR	L858R	L858R	Non-Small Cell Lung Cancer	1	Erlotinib, Afatinib, Osimertinib, Dacomitinib, Gefitinib	28958502, 23816960, 30659024, 20022809, 21670455, 29151359, 22452895, 25589191, 22285168, 29864379, 19692680, 27987585, 22370314, 20573926	
ENST00000275493	NM_005228.3	1956	EGFR	L861	L861	Non-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib	21531810, 28336552, 26051236	
ENST00000275493	NM_005228.3	1956	EGFR	M277E	M277E	Non-Small Cell Lung Cancer	1	Erlotinib, Afatinib, Gefitinib	28979142	
ENST00000275493	NM_005228.3	1956	EGFR	S768I	S768I	Non-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib	17285735, 28336552, 25521405, 26051236	
ENST00000275493	NM_005228.3	1956	EGFR	T790M	T790M	Non-Small Cell Lung Cancer	1	Osimertinib	25923549, 30059262, 27751847, 29151359	
ENST00000269571	NM_004448.2	2064	ERBB2	Amplification	Amplification	Breast Cancer	1	Lapatinib + Trastuzumab, Pertuzumab + Trastuzumab, Ado-Trastuzumab Emtansine, Lapatinib, Neratinib, Trastuzumab	30860945, 22149875, 16236738, 19060928, 19786658, 22153890, 26874901, 30516102, 29320312, 22257673, 23020162, 29146401, 16091755, 23602601, 30274983, 17192538	
ENST00000269571	NM_004448.2	2064	ERBB2	Amplification	Amplification	Esophagogastric Cancer	1	Trastuzumab	20728210	
ENST00000358487	NM_000141.4	2263	FGFR2	Fusions	Fusions	Bladder Cancer	1	Erdafitinib	26324363, 31340094	
ENST00000260795	NM_000142.4	2261	FGFR3	Fusions	Fusions	Bladder Cancer	1	Erdafitinib	26324363, 31340094	
ENST00000260795	NM_000142.4	2261	FGFR3	G370C	G370C	Bladder Cancer	1	Erdafitinib	26324363, 31340094	
ENST00000260795	NM_000142.4	2261	FGFR3	R248C	R248C	Bladder Cancer	1	Erdafitinib	26324363, 31340094	
ENST00000260795	NM_000142.4	2261	FGFR3	S249C	S249C	Bladder Cancer	1	Erdafitinib	26324363, 31340094	
ENST00000260795	NM_000142.4	2261	FGFR3	Y373C	Y373C	Bladder Cancer	1	Erdafitinib	26324363, 31340094	
ENST00000241453	NM_004119.2	2322	FLT3	Internal tandem duplication	572_630ins	Acute Myeloid Leukemia	1	Gilteritinib	28645776, 28516360	
ENST00000241453	NM_004119.2	2322	FLT3	Oncogenic Mutations	Oncogenic Mutations	Acute Myeloid Leukemia	1	Midostaurin + High Dose Chemotherapy	28644114	
ENST00000345146	NM_005896.2	3417	IDH1	Oncogenic Mutations	Oncogenic Mutations	Acute Myeloid Leukemia	1	Ivosidenib	23393090, 23558169, 29860938	Hansen et al. Abstract# 3734, ASH 2014 http://www.bloodjournal.org/content/124/21/3734?sso-checked=true
ENST00000330062	NM_002168.2	3418	IDH2	Oncogenic Mutations	Oncogenic Mutations	Acute Myeloid Leukemia	1	Enasidenib	28588020	
ENST00000288135	NM_000222.2	3815	KIT	Exon 17 mutations	C788_N828mut	Gastrointestinal Stromal Tumor	1	Regorafenib	23177515	
ENST00000288135	NM_000222.2	3815	KIT	Oncogenic Mutations	Oncogenic Mutations	Gastrointestinal Stromal Tumor	1	Regorafenib, Imatinib, Sunitinib	28196207, 18955451, 18235122, 12181401, 17046465, 23177515	
ENST00000288135	NM_000222.2	3815	KIT	T670I	T670I	Gastrointestinal Stromal Tumor	1	Regorafenib, Sunitinib	17046465, 17699867, 23177515	
ENST00000288135	NM_000222.2	3815	KIT	V654A	V654A	Gastrointestinal Stromal Tumor	1	Regorafenib, Sunitinib	17046465, 23177515	
ENST00000256078	NM_033360.2	3845	KRAS	Wildtype	Wildtype	Colorectal Cancer	1	Regorafenib, Panitumumab, Cetuximab	31268481, 20921462, 24739896, 20921465, 19339720, 23177514, 15677699	
ENST00000524377	NM_002529.3	4914	NTRK1	Fusions	Fusions	All Solid Tumors	1	Larotrectinib	26216294, 29466156	
ENST00000277120	NM_006180.3	4915	NTRK2	Fusions	Fusions	All Solid Tumors	1	Larotrectinib	26216294, 29466156	
ENST00000360948	NM_001012338.2	4916	NTRK3	Fusions	Fusions	All Solid Tumors	1	Larotrectinib	26216294, 29466156	
null	null	-2	Other Biomarkers	Microsatellite Instability-High	MSI-H	All Solid Tumors	1	Pembrolizumab	30589920, 28596308, 26028255	
null	null	-2	Other Biomarkers	Microsatellite Instability-High	MSI-H	Colorectal Cancer	1	Nivolumab	28734759	Andre et al. Abstract# 553, GCS 2018 https://meetinglibrary.asco.org/record/155742/abstract
ENST00000331163	NM_002608.2	5155	PDGFB	COL1A1-PDGFB Fusion	COL1A1-PDGFB Fusion	Dermatofibrosarcoma Protuberans	1	Imatinib	20439456, 21128251, 15503291, 15746584, 18451237, 15681532, 19620561	
ENST00000257290	NM_006206.4	5156	PDGFRA	FIP1L1-PDGFRA Fusion	FIP1L1-PDGFRA Fusion	Chronic Eosinophilic Leukemia, NOS	1	Imatinib	18950453	
ENST00000257290	NM_006206.4	5156	PDGFRA	Fusions	Fusions	Myelodysplastic/Myeloproliferative Neoplasms	1	Imatinib	12944919, 17555450, 12660384, 16498388, 14504092, 16845659, 18950453, 15034867	
ENST00000261799	NM_002609.3	5159	PDGFRB	Fusions	Fusions	Myelodysplastic/Myeloproliferative Neoplasms	1	Imatinib	16960151, 12676775, 12181402, 14504092, 18950453, 24687085, 22897847, 26355392, 1516603	
ENST00000263967	NM_006218.2	5290	PIK3CA	Oncogenic Mutations	Oncogenic Mutations	Breast Cancer	1	Alpelisib + Fulvestrant	25877889, 30543347, 31091374	
ENST00000368508	NM_002944.2	6098	ROS1	Fusions	Fusions	Non-Small Cell Lung Cancer	1	Crizotinib	30980071, 25264305, 29596029	
ENST00000298552	NM_000368.4	7248	TSC1	Oncogenic Mutations	Oncogenic Mutations	CNS Cancer	1	Everolimus	23158522	
ENST00000219476	NM_000548.3	7249	TSC2	Oncogenic Mutations	Oncogenic Mutations	CNS Cancer	1	Everolimus	23158522	
ENST00000318560	NM_005157.4	25	ABL1	BCR-ABL1 Fusion	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	2A	Nilotinib, Bosutinib	15071128, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	E255K	E255K	B-Lymphoblastic Leukemia/Lymphoma	2A	Dasatinib, Bosutinib	25368968, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	E255V	E255V	B-Lymphoblastic Leukemia/Lymphoma	2A	Dasatinib, Bosutinib	25368968, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	F317C	F317C	B-Lymphoblastic Leukemia/Lymphoma	2A	Nilotinib, Bosutinib	15071128, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	F317I	F317I	B-Lymphoblastic Leukemia/Lymphoma	2A	Nilotinib, Bosutinib	15071128, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	F317L	F317L	B-Lymphoblastic Leukemia/Lymphoma	2A	Nilotinib, Bosutinib	15071128, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	F317V	F317V	B-Lymphoblastic Leukemia/Lymphoma	2A	Nilotinib, Bosutinib	15071128, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	F359C	F359C	B-Lymphoblastic Leukemia/Lymphoma	2A	Dasatinib, Bosutinib	25368968, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	F359I	F359I	B-Lymphoblastic Leukemia/Lymphoma	2A	Dasatinib, Bosutinib	25368968, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	F359V	F359V	B-Lymphoblastic Leukemia/Lymphoma	2A	Dasatinib, Bosutinib	25368968, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	T315A	T315A	B-Lymphoblastic Leukemia/Lymphoma	2A	Nilotinib, Bosutinib	15071128, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	V299L	V299L	B-Lymphoblastic Leukemia/Lymphoma	2A	Nilotinib	15071128	
ENST00000318560	NM_005157.4	25	ABL1	Y253H	Y253H	B-Lymphoblastic Leukemia/Lymphoma	2A	Dasatinib, Bosutinib	25368968, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	E255K	E255K	Chronic Myelogenous Leukemia	2A	Dasatinib, Bosutinib	15930265, 19779040, 28599428, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	E255V	E255V	Chronic Myelogenous Leukemia	2A	Dasatinib, Bosutinib	15930265, 19779040, 28599428, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	F317C	F317C	Chronic Myelogenous Leukemia	2A	Nilotinib, Bosutinib	15930265, 28599428, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	F317I	F317I	Chronic Myelogenous Leukemia	2A	Nilotinib, Bosutinib	15930265, 28599428, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	F317L	F317L	Chronic Myelogenous Leukemia	2A	Nilotinib, Bosutinib	15930265, 28599428, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	F317V	F317V	Chronic Myelogenous Leukemia	2A	Nilotinib, Bosutinib	15930265, 28599428, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	F359C	F359C	Chronic Myelogenous Leukemia	2A	Dasatinib, Bosutinib	15930265, 19779040, 28599428, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	F359I	F359I	Chronic Myelogenous Leukemia	2A	Dasatinib, Bosutinib	15930265, 19779040, 28599428, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	F359V	F359V	Chronic Myelogenous Leukemia	2A	Dasatinib, Bosutinib	15930265, 19779040, 28599428, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	T315A	T315A	Chronic Myelogenous Leukemia	2A	Nilotinib, Bosutinib	15930265, 28599428, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	V299L	V299L	Chronic Myelogenous Leukemia	2A	Nilotinib	15930265, 19075254	
ENST00000318560	NM_005157.4	25	ABL1	Y253H	Y253H	Chronic Myelogenous Leukemia	2A	Dasatinib, Bosutinib	15930265, 19779040, 28599428, 19075254	
ENST00000389048	NM_004304.4	238	ALK	Fusions	Fusions	Inflammatory Myofibroblastic Tumor	2A	Crizotinib, Ceritinib	26020125, 24670165, 20979472, 23598171	Trahair et al. JCO PO, 2018 https://ascopubs.org/doi/full/10.1200/PO.18.00297
ENST00000288602	NM_004333.4	673	BRAF	V600E	V600E	Colorectal Cancer	2A	Encorafenib + Binimetinib + Cetuximab, Panitumumab + Dabrafenib + Trametinib	29431699	Kopetz et al. Abstract# LBA-006, ESMO 2019 https://academic.oup.com/annonc/article/30/Supplement_4/mdz183.004/5526665
ENST00000288602	NM_004333.4	673	BRAF	V600E	V600E	Hairy Cell Leukemia	2A	Vemurafenib	26352686	
ENST00000357654	NM_007294.3	672	BRCA1	Oncogenic Mutations	Oncogenic Mutations	Breast Cancer	2A	Talazoparib, Olaparib	30110579, 30563931, 28578601	
ENST00000357654	NM_007294.3	672	BRCA1	Oncogenic Mutations	Oncogenic Mutations	Ovarian Cancer	2A	Olaparib	25366685, 30285518, 30345884, 24882434	
ENST00000357654	NM_007294.3	672	BRCA1	Oncogenic Mutations	Oncogenic Mutations	Peritoneal Serous Carcinoma	2A	Olaparib	25366685, 30285518, 30345884, 24882434	
ENST00000380152	NM_000059.3	675	BRCA2	Oncogenic Mutations	Oncogenic Mutations	Breast Cancer	2A	Talazoparib, Olaparib	30110579, 30563931, 28578601	
ENST00000380152	NM_000059.3	675	BRCA2	Oncogenic Mutations	Oncogenic Mutations	Ovarian Cancer	2A	Olaparib	25366685, 30285518, 30345884, 24882434	
ENST00000380152	NM_000059.3	675	BRCA2	Oncogenic Mutations	Oncogenic Mutations	Peritoneal Serous Carcinoma	2A	Olaparib	25366685, 30285518, 30345884, 24882434	
ENST00000257904	NM_000075.3	1019	CDK4	Amplification	Amplification	Dedifferentiated Liposarcoma	2A	Abemaciclib, Palbociclib	23569312, 27124835	
ENST00000257904	NM_000075.3	1019	CDK4	Amplification	Amplification	Well-Differentiated Liposarcoma	2A	Abemaciclib, Palbociclib	23569312, 27124835	
ENST00000269571	NM_004448.2	2064	ERBB2	Amplification	Amplification	Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma	2A	Carboplatin-Taxol Regimen + Trastuzumab	29584549	
ENST00000288135	NM_000222.2	3815	KIT	Exon 17 mutations	C788_N828mut	Gastrointestinal Stromal Tumor	2A	Sorafenib	23140824, 22270258	Kindler et al. Abstract# 10009, ASCO 2011 http://meetinglibrary.asco.org/content/80567-102
ENST00000288135	NM_000222.2	3815	KIT	D816	D816	Melanoma	2A	Imatinib	23775962, 21642685	
ENST00000288135	NM_000222.2	3815	KIT	Exon 17 mutations	C788_N828mut	Melanoma	2A	Imatinib	23775962, 21642685	
ENST00000288135	NM_000222.2	3815	KIT	Oncogenic Mutations	Oncogenic Mutations	Melanoma	2A	Imatinib	23775962, 21642685	
ENST00000288135	NM_000222.2	3815	KIT	T670I	T670I	Melanoma	2A	Imatinib	23775962, 21642685	
ENST00000288135	NM_000222.2	3815	KIT	V654A	V654A	Melanoma	2A	Imatinib	23775962, 21642685	
ENST00000288135	NM_000222.2	3815	KIT	D816	D816	Thymic Tumor	2A	Sunitinib, Sorafenib	14991904, 25592632, 19461405, 20571495	
ENST00000288135	NM_000222.2	3815	KIT	Exon 17 mutations	C788_N828mut	Thymic Tumor	2A	Sunitinib, Sorafenib	14991904, 25592632, 19461405, 20571495	
ENST00000288135	NM_000222.2	3815	KIT	Oncogenic Mutations	Oncogenic Mutations	Thymic Tumor	2A	Sunitinib, Sorafenib	14991904, 25592632, 19461405, 20571495	
ENST00000288135	NM_000222.2	3815	KIT	T670I	T670I	Thymic Tumor	2A	Sunitinib, Sorafenib	14991904, 25592632, 19461405, 20571495	
ENST00000288135	NM_000222.2	3815	KIT	V654A	V654A	Thymic Tumor	2A	Sunitinib, Sorafenib	14991904, 25592632, 19461405, 20571495	
ENST00000397752	NM_000245.2	4233	MET	Amplification	Amplification	Non-Small Cell Lung Cancer	2A	Crizotinib	21623265, 25971939, 26729443	Camidge et al. Abstract# 8001, ASCO 2014 http://meetinglibrary.asco.org/content/132030-144
ENST00000397752	NM_000245.2	4233	MET	D1010H	D1010H	Non-Small Cell Lung Cancer	2A	Crizotinib	21623265, 25971939, 26729443	Camidge et al. Abstract# 8001, ASCO 2014 http://meetinglibrary.asco.org/content/132030-144
ENST00000397752	NM_000245.2	4233	MET	D1010N	D1010N	Non-Small Cell Lung Cancer	2A	Crizotinib	21623265, 25971939, 26729443	Camidge et al. Abstract# 8001, ASCO 2014 http://meetinglibrary.asco.org/content/132030-144
ENST00000397752	NM_000245.2	4233	MET	D1010Y	D1010Y	Non-Small Cell Lung Cancer	2A	Crizotinib	21623265, 25971939, 26729443	Camidge et al. Abstract# 8001, ASCO 2014 http://meetinglibrary.asco.org/content/132030-144
ENST00000397752	NM_000245.2	4233	MET	Exon 14 Deletion	963_1010del	Non-Small Cell Lung Cancer	2A	Crizotinib	21623265, 25971939, 26729443	Camidge et al. Abstract# 8001, ASCO 2014 http://meetinglibrary.asco.org/content/132030-144
ENST00000397752	NM_000245.2	4233	MET	Exon 14 splice mutation	963_1010splice	Non-Small Cell Lung Cancer	2A	Crizotinib	21623265, 25971939, 26729443	Camidge et al. Abstract# 8001, ASCO 2014 http://meetinglibrary.asco.org/content/132030-144
ENST00000397752	NM_000245.2	4233	MET	Y1003C	Y1003C	Non-Small Cell Lung Cancer	2A	Crizotinib	21623265, 25971939, 26729443	Camidge et al. Abstract# 8001, ASCO 2014 http://meetinglibrary.asco.org/content/132030-144
ENST00000397752	NM_000245.2	4233	MET	Y1003F	Y1003F	Non-Small Cell Lung Cancer	2A	Crizotinib	21623265, 25971939, 26729443	Camidge et al. Abstract# 8001, ASCO 2014 http://meetinglibrary.asco.org/content/132030-144
ENST00000397752	NM_000245.2	4233	MET	Y1003N	Y1003N	Non-Small Cell Lung Cancer	2A	Crizotinib	21623265, 25971939, 26729443	Camidge et al. Abstract# 8001, ASCO 2014 http://meetinglibrary.asco.org/content/132030-144
ENST00000397752	NM_000245.2	4233	MET	Amplification	Amplification	Renal Cell Carcinoma	2A	Cabozantinib	27279544, 27462141	
ENST00000257290	NM_006206.4	5156	PDGFRA	D842V	D842V	Gastrointestinal Stromal Tumor	2A	Dasatinib		Trent et al. Abstract# 10006, ASCO 2011 http://meetinglibrary.asco.org/content/79120-102
ENST00000257290	NM_006206.4	5156	PDGFRA	Oncogenic Mutations	Oncogenic Mutations	Gastrointestinal Stromal Tumor	2A	Imatinib	22718859	
ENST00000355710	NM_020975.4	5979	RET	Fusions	Fusions	Non-Small Cell Lung Cancer	2A	Cabozantinib, Vandetanib	27803005, 28447912, 27825636, 23533264	
ENST00000298552	NM_000368.4	7248	TSC1	Oncogenic Mutations	Oncogenic Mutations	Renal Cell Carcinoma	2A	Everolimus	30327302, 26831717	
ENST00000219476	NM_000548.3	7249	TSC2	Oncogenic Mutations	Oncogenic Mutations	Renal Cell Carcinoma	2A	Everolimus	30327302, 26831717	
ENST00000318560	NM_005157.4	25	ABL1	BCR-ABL1 Fusion	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	3A	Asciminib		Mauro, M. et al. Abstract# TPS7081, ASCO 2018 http://abstracts.asco.org/214/AbstView_214_220317.html
ENST00000349310	NM_001014431.1	207	AKT1	E17K	E17K	Breast Cancer	3A	AZD5363	22294718, 23394218, 28489509, 26351323	
ENST00000349310	NM_001014431.1	207	AKT1	E17K	E17K	Endometrial Cancer	3A	AZD5363	22294718, 23394218, 28489509, 26351323	
ENST00000349310	NM_001014431.1	207	AKT1	E17K	E17K	Ovarian Cancer	3A	AZD5363	22294718, 23394218, 28489509, 26351323	
ENST00000377045	NM_001654.4	369	ARAF	Oncogenic Mutations	Oncogenic Mutations	Histiocytosis	3A	Cobimetinib, Sorafenib	24569458, 29236635, 26566875, 30867592	
ENST00000377045	NM_001654.4	369	ARAF	Oncogenic Mutations	Oncogenic Mutations	Non-Small Cell Lung Cancer	3A	Sorafenib	24569458	
ENST00000288602	NM_004333.4	673	BRAF	V600	V600	Colorectal Cancer	3A	Vemurafenib + Panitumumab, Panitumumab + Dabrafenib + Trametinib	19884556, 29431699, 20619739, 25589621, 19001320, 22448344	Bendell, J et al. Abstract#3515, J Clin Oncol, 32, 2014 http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.3515; Kopetz, S. et al. Abstract#3534. J. Clin. Oncol. 28. 2010 http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.3534
ENST00000288602	NM_004333.4	673	BRAF	Oncogenic Mutations	Oncogenic Mutations	Histiocytosis	3A	Cobimetinib	29236635, 30867592	
ENST00000288602	NM_004333.4	673	BRAF	Fusions	Fusions	Melanoma	3A	Cobimetinib, Trametinib	26314551, 23890088, 24345920, 26072686	
ENST00000288602	NM_004333.4	673	BRAF	K601	K601	Melanoma	3A	Trametinib	22798288, 28344857, 24933606, 23248257, 29903896	
ENST00000288602	NM_004333.4	673	BRAF	L597	L597	Melanoma	3A	Trametinib	22798288, 24933606, 29903896	
ENST00000288602	NM_004333.4	673	BRAF	Fusions	Fusions	Ovarian Cancer	3A	Cobimetinib, Trametinib	23890088, 26324360, 24345920	
ENST00000275493	NM_005228.3	1956	EGFR	Exon 20 insertion	762_823ins	Non-Small Cell Lung Cancer	3A	Poziotinib	27188206, 29686424	Heymach et al. Abstract# OA02.06, WCLC 2018 https://wclc2018.iaslc.org/wp-content/uploads/2018/09/WCLC2018-Abstract-Book_vF-LR-REV-SEPT-25-2018.pdf
ENST00000269571	NM_004448.2	2064	ERBB2	Oncogenic Mutations	Oncogenic Mutations	Breast Cancer	3A	Neratinib	23220880, 29420467	
ENST00000269571	NM_004448.2	2064	ERBB2	Oncogenic Mutations	Oncogenic Mutations	Non-Small Cell Lung Cancer	3A	Ado-Trastuzumab Emtansine, Neratinib	23220880, 30206164, 29989854, 29420467	
ENST00000391945	NM_000400.3	2068	ERCC2	Oncogenic Mutations	Oncogenic Mutations	Bladder Cancer	3A	Cisplatin	12208738, 25096233, 29980530, 27310333	
ENST00000206249	NM_001122740.1	2099	ESR1	Oncogenic Mutations	Oncogenic Mutations	Breast Cancer	3A	AZD9496, Fulvestrant	27986707, 27269946	
ENST00000320356	NM_004456.4	2146	EZH2	Oncogenic Mutations	Oncogenic Mutations	Follicular Lymphoma	3A	Tazemetostat		Morschhauser et al. Abstract# S100, EHA 2018 https://library.ehaweb.org/eha/2018/stockholm/214434/gilles.salles.interim.update.from.a.phase.2.multicenter.study.of.tazemetostat.html?f=topic=1574*media=3%27
ENST00000425967	NM_001174067.1	2260	FGFR1	Amplification	Amplification	Lung Squamous Cell Carcinoma	3A	AZD4547, BGJ398, Erdafitinib, Debio1347	27870574, 23082000, 30745300	
ENST00000358487	NM_000141.4	2263	FGFR2	Fusions	Fusions	Bladder Cancer	3A	AZD4547, BGJ398, Debio1347	27870574, 24122810, 30745300	
ENST00000358487	NM_000141.4	2263	FGFR2	Fusions	Fusions	Cholangiocarcinoma	3A	AZD4547, Erdafitinib, BGJ398, Debio1347	31088831, 29182496, 24122810, 30745300	Cleary et al. Abstract# 447, Gastrointestinal Cancer Symposium, 2018 https://meetinglibrary.asco.org/record/155948/abstract
ENST00000260795	NM_000142.4	2261	FGFR3	Fusions	Fusions	Bladder Cancer	3A	AZD4547, BGJ398, Debio1347	29848605, 22837387, 30745300	
ENST00000260795	NM_000142.4	2261	FGFR3	G370C	G370C	Bladder Cancer	3A	AZD4547, BGJ398, Debio1347	21119661, 29848605, 27870574, 30745300	
ENST00000260795	NM_000142.4	2261	FGFR3	G380R	G380R	Bladder Cancer	3A	AZD4547, Erdafitinib, BGJ398, Debio1347	21119661, 31088831, 29848605, 26324363, 27870574, 30745300	Siefker-Radtke et al. Abstract#4503, ASCO 2018 https://meetinglibrary.asco.org/record/160559/abstract
ENST00000260795	NM_000142.4	2261	FGFR3	K650	K650	Bladder Cancer	3A	AZD4547, Erdafitinib, BGJ398, Debio1347	21119661, 31088831, 29848605, 26324363, 27870574, 30745300	Siefker-Radtke et al. Abstract#4503, ASCO 2018 https://meetinglibrary.asco.org/record/160559/abstract
ENST00000260795	NM_000142.4	2261	FGFR3	R248C	R248C	Bladder Cancer	3A	AZD4547, BGJ398, Debio1347	21119661, 29848605, 27870574, 30745300	
ENST00000260795	NM_000142.4	2261	FGFR3	S249C	S249C	Bladder Cancer	3A	AZD4547, BGJ398, Debio1347	21119661, 29848605, 27870574, 30745300	
ENST00000260795	NM_000142.4	2261	FGFR3	S371C	S371C	Bladder Cancer	3A	AZD4547, Erdafitinib, BGJ398, Debio1347	21119661, 31088831, 29848605, 26324363, 27870574, 30745300	Siefker-Radtke et al. Abstract#4503, ASCO 2018 https://meetinglibrary.asco.org/record/160559/abstract
ENST00000260795	NM_000142.4	2261	FGFR3	Y373C	Y373C	Bladder Cancer	3A	AZD4547, BGJ398, Debio1347	21119661, 29848605, 27870574, 30745300	
ENST00000241453	NM_004119.2	2322	FLT3	Internal tandem duplication	572_630ins	Acute Myeloid Leukemia	3A	Crenolanib, Sorafenib, Quizartinib	18230792, 22368270, 24227820, 29859851, 29875101	Cortes, J. et al. Abstract# LB2600, EHA 2017 https://learningcenter.ehaweb.org/eha/2018/stockholm/218882/jorge.cortes.quizartinib.significantly.prolongs.overall.survival.in.patients.html; Wang E. et al. Abstract# P552, EHA Congress 2017 https://learningcenter.ehaweb.org/eha/2017/22nd/181839/eunice.wang.variant.flt3.mutations.can.be.eradicated.by.cytarabine.html
ENST00000311189	NM_001130442.1	3265	HRAS	Oncogenic Mutations	Oncogenic Mutations	Head and Neck Squamous Cell Carcinoma	3A	Tipifarnib	12497061, 24240680	Ho et al. Abstract# TPS2618, JCO 2017 http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS2618
ENST00000381652	NM_004972.3	3717	JAK2	PCM1-JAK2 Fusion	PCM1-JAK2 Fusion	Chronic Eosinophilic Leukemia, NOS	3A	Ruxolitinib	22899477, 25207766, 26202607, 23630205, 22875628, 25515960, 23400675, 25260694	
ENST00000288135	NM_000222.2	3815	KIT	D816	D816	Mastocytosis	3A	Avapritinib	29233825, 30274985	DeAngelo et al. Blood 2017 130:2, ASH 2017 http://www.bloodjournal.org/content/130/Suppl_1/2; Drummond et al. Blood 128:477, ASH 2016 http://www.bloodjournal.org/content/128/22/477
ENST00000256078	NM_033360.2	3845	KRAS	Oncogenic Mutations	Oncogenic Mutations	Histiocytosis	3A	Cobimetinib	29236635, 30867592	
ENST00000307102	NM_002755.3	5604	MAP2K1	Oncogenic Mutations	Oncogenic Mutations	Histiocytosis	3A	Cobimetinib, Trametinib	25351745, 26324360, 26566875, 30867592, 25370473	Papapanagiotou et al. JCOPO, 2017 http://ascopubs.org/doi/full/10.1200/PO.16.00070
ENST00000307102	NM_002755.3	5604	MAP2K1	Oncogenic Mutations	Oncogenic Mutations	Low-Grade Serous Ovarian Cancer	3A	Cobimetinib, Trametinib	25351745, 26324360, 26566875, 30867592, 25370473	Papapanagiotou et al. JCOPO, 2017 http://ascopubs.org/doi/full/10.1200/PO.16.00070
ENST00000307102	NM_002755.3	5604	MAP2K1	Oncogenic Mutations	Oncogenic Mutations	Melanoma	3A	Cobimetinib, Trametinib	25351745, 26324360, 26566875, 30867592, 25370473	Papapanagiotou et al. JCOPO, 2017 http://ascopubs.org/doi/full/10.1200/PO.16.00070
ENST00000307102	NM_002755.3	5604	MAP2K1	Oncogenic Mutations	Oncogenic Mutations	Non-Small Cell Lung Cancer	3A	Cobimetinib, Trametinib	25351745, 26324360, 26566875, 30867592, 25370473	Papapanagiotou et al. JCOPO, 2017 http://ascopubs.org/doi/full/10.1200/PO.16.00070
ENST00000262948	NM_030662.3	5605	MAP2K2	Oncogenic Mutations	Oncogenic Mutations	Histiocytosis	3A	Cobimetinib	29236635, 30867592	
ENST00000462284	NM_002392.5	4193	MDM2	Amplification	Amplification	Liposarcoma	3A	Milademetan Tosylate, RO5045337	23400593, 23084521	Gounder et al. Abstract# 19 3025592, CTOS 2018 https://www.retesarcoma.it/wp-content/uploads/2018/10/2018-ctos-final-program.pdf; Gounder et al. Abstract# 2581, ASCO 2016 http://meetinglibrary.asco.org/content/166204-176; Bauer T et al. Abstract# B27, AACR 2015 http://mct.aacrjournals.org/content/14/12_Supplement_2/B27
ENST00000397752	NM_000245.2	4233	MET	D1010H	D1010H	Non-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib	21918175, 25971939, 25971938, 27693535	Schuler et al. Abstract# 9067, ASCO 2016 http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9067
ENST00000397752	NM_000245.2	4233	MET	D1010N	D1010N	Non-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib	21918175, 25971939, 25971938, 27693535	Schuler et al. Abstract# 9067, ASCO 2016 http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9067
ENST00000397752	NM_000245.2	4233	MET	D1010Y	D1010Y	Non-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib	21918175, 25971939, 25971938, 27693535	Schuler et al. Abstract# 9067, ASCO 2016 http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9067
ENST00000397752	NM_000245.2	4233	MET	Exon 14 Deletion	963_1010del	Non-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib	21918175, 25971939, 25971938, 27693535	Schuler et al. Abstract# 9067, ASCO 2016 http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9067
ENST00000397752	NM_000245.2	4233	MET	Exon 14 splice mutation	963_1010splice	Non-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib	21918175, 25971939, 25971938, 27693535	Schuler et al. Abstract# 9067, ASCO 2016 http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9067
ENST00000397752	NM_000245.2	4233	MET	Y1003C	Y1003C	Non-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib	21918175, 25971939, 25971938, 27693535	Schuler et al. Abstract# 9067, ASCO 2016 http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9067
ENST00000397752	NM_000245.2	4233	MET	Y1003F	Y1003F	Non-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib	21918175, 25971939, 25971938, 27693535	Schuler et al. Abstract# 9067, ASCO 2016 http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9067
ENST00000397752	NM_000245.2	4233	MET	Y1003N	Y1003N	Non-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib	21918175, 25971939, 25971938, 27693535	Schuler et al. Abstract# 9067, ASCO 2016 http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9067
ENST00000361445	NM_004958.3	2475	MTOR	E2014K	E2014K	Bladder Cancer	3A	Everolimus	24625776, 23551593	
ENST00000361445	NM_004958.3	2475	MTOR	E2419K	E2419K	Bladder Cancer	3A	Everolimus	24625776, 23551593	
ENST00000361445	NM_004958.3	2475	MTOR	L1460P	L1460P	Renal Cell Carcinoma	3A	Temsirolimus	26831717	
ENST00000361445	NM_004958.3	2475	MTOR	L2209V	L2209V	Renal Cell Carcinoma	3A	Temsirolimus	26831717	
ENST00000361445	NM_004958.3	2475	MTOR	L2427Q	L2427Q	Renal Cell Carcinoma	3A	Temsirolimus	26831717	
ENST00000361445	NM_004958.3	2475	MTOR	Q2223K	Q2223K	Renal Cell Carcinoma	3A	Everolimus	24622468	
ENST00000369535	NM_002524.4	4893	NRAS	Oncogenic Mutations	Oncogenic Mutations	Histiocytosis	3A	Cobimetinib	29236635, 30867592	
ENST00000369535	NM_002524.4	4893	NRAS	Oncogenic Mutations	Oncogenic Mutations	Melanoma	3A	Binimetinib, Binimetinib + Ribociclib	16273091, 28284557, 22983396	Schuler et al. Abstract #9519, ASCO 2017 http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9519
ENST00000369535	NM_002524.4	4893	NRAS	Oncogenic Mutations	Oncogenic Mutations	Thyroid Cancer	3A	Iodine I 131-6-Beta-Iodomethyl-19-Norcholesterol + Selumetinib	22105174, 23406027	
ENST00000524377	NM_002529.3	4914	NTRK1	Fusions	Fusions	All Solid Tumors	3A	Entrectinib	28183697	Demetri et al. Abstract# LBA17, ESMO 2018 Congress https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583; Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018 https://meetinglibrary.asco.org/record/155954/abstract
ENST00000277120	NM_006180.3	4915	NTRK2	Fusions	Fusions	All Solid Tumors	3A	Entrectinib	28183697	Demetri et al. Abstract# LBA17, ESMO 2018 Congress https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583; Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018 https://meetinglibrary.asco.org/record/155954/abstract
ENST00000360948	NM_001012338.2	4916	NTRK3	Fusions	Fusions	All Solid Tumors	3A	Entrectinib	28183697	Demetri et al. Abstract# LBA17, ESMO 2018 Congress https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583; Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018 https://meetinglibrary.asco.org/record/155954/abstract
ENST00000263967	NM_006218.2	5290	PIK3CA	Oncogenic Mutations	Oncogenic Mutations	Breast Cancer	3A	Buparlisib, Serabelisib, Copanlisib, GDC-0077, Taselisib + Fulvestrant, Alpelisib, Buparlisib + Fulvestrant, Taselisib	22049316, 25877889, 29401002, 28490463, 29793946, 24652201, 30715997, 24608574, 23662903, 22188813, 27672108, 25172762	Staben et al. Abstract# DDT02-01, AACR 2017 http://www.abstractsonline.com/pp8/#!/4292/presentation/11034; Di Leo et al. Abstract# S4-07, SABCS 2016 http://cancerres.aacrjournals.org/content/77/4_Supplement/S4-07; Dickler et al. Abstract# 520, ASCO 2016 http://meetinglibrary.asco.org/content/165518-176; Wade et al. Abstract# 9054, ASCO 2017 http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9054; Edgar et al. Abstract# 156, AACR 2017 http://cancerres.aacrjournals.org/content/77/13_Supplement/156
ENST00000331920	NM_000264.3	5727	PTCH1	Truncating Mutations	Truncating Mutations	Embryonal Tumor	3A	Sonidegib	24900187, 24523439	
ENST00000331920	NM_000264.3	5727	PTCH1	Truncating Mutations	Truncating Mutations	Skin Cancer, Non-Melanoma	3A	Sonidegib, Vismodegib	29320312, 24900187, 22670903, 22670904, 24523439	
ENST00000251849	NM_002880.3	5894	RAF1	Oncogenic Mutations	Oncogenic Mutations	Histiocytosis	3A	Cobimetinib	29236635, 30867592	
ENST00000355710	NM_020975.4	5979	RET	Oncogenic Mutations	Oncogenic Mutations	Medullary Thyroid Cancer	3A	LOXO-292, BLU-667	29912274, 29657135	Drilon et al. Abstract# 102, ASCO 2018 https://meetinglibrary.asco.org/record/161573/abstract
ENST00000355710	NM_020975.4	5979	RET	Fusions	Fusions	Non-Small Cell Lung Cancer	3A	LOXO-292, BLU-667	29912274, 29657135	Drilon et al. Abstract# 102, ASCO 2018 https://meetinglibrary.asco.org/record/161573/abstract
ENST00000278616	NM_000051.3	472	ATM	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	Olaparib	26510020	
ENST00000288602	NM_004333.4	673	BRAF	G464	G464	All Solid Tumors	4	PLX8394	26466569, 28659148, 28783719, 30559419	Janku et al. Abstract# B176, AACR-NCI-EORTC 2017 http://mct.aacrjournals.org/content/17/1_Supplement/B176
ENST00000288602	NM_004333.4	673	BRAF	G469A	G469A	All Solid Tumors	4	PLX8394	26466569, 28659148, 28783719, 30559419	Janku et al. Abstract# B176, AACR-NCI-EORTC 2017 http://mct.aacrjournals.org/content/17/1_Supplement/B176
ENST00000288602	NM_004333.4	673	BRAF	G469R	G469R	All Solid Tumors	4	PLX8394	26466569, 28659148, 28783719, 30559419	Janku et al. Abstract# B176, AACR-NCI-EORTC 2017 http://mct.aacrjournals.org/content/17/1_Supplement/B176
ENST00000288602	NM_004333.4	673	BRAF	G469V	G469V	All Solid Tumors	4	PLX8394	26466569, 28659148, 28783719, 30559419	Janku et al. Abstract# B176, AACR-NCI-EORTC 2017 http://mct.aacrjournals.org/content/17/1_Supplement/B176
ENST00000288602	NM_004333.4	673	BRAF	K601	K601	All Solid Tumors	4	PLX8394	26466569, 28659148, 28783719, 30559419	Janku et al. Abstract# B176, AACR-NCI-EORTC 2017 http://mct.aacrjournals.org/content/17/1_Supplement/B176
ENST00000288602	NM_004333.4	673	BRAF	L597	L597	All Solid Tumors	4	PLX8394	26466569, 28659148, 28783719, 30559419	Janku et al. Abstract# B176, AACR-NCI-EORTC 2017 http://mct.aacrjournals.org/content/17/1_Supplement/B176
ENST00000447079	NM_016507.2	51755	CDK12	Truncating Mutations	Truncating Mutations	All Solid Tumors	4	Pembrolizumab, Nivolumab, Cemiplimab	29906450	
ENST00000304494	NM_000077.4	1029	CDKN2A	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	Abemaciclib, Palbociclib, Ribociclib	19874578, 25941111, 24495407, 29232554, 28283584	
ENST00000275493	NM_005228.3	1956	EGFR	A289V	A289V	Glioma	4	Lapatinib	18334972, 20459769, 22588883	
ENST00000275493	NM_005228.3	1956	EGFR	Amplification	Amplification	Glioma	4	Lapatinib	18334972, 20459769, 22588883	
ENST00000275493	NM_005228.3	1956	EGFR	R108K	R108K	Glioma	4	Lapatinib	18334972, 20459769, 22588883	
ENST00000275493	NM_005228.3	1956	EGFR	T263P	T263P	Glioma	4	Lapatinib	18334972, 20459769, 22588883	
ENST00000275493	NM_005228.3	1956	EGFR	D761Y	D761Y	Non-Small Cell Lung Cancer	4	Osimertinib	28424065, 17085664	
ENST00000425967	NM_001174067.1	2260	FGFR1	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	AZD4547, BGJ398, Erdafitinib, Debio1347	26438159, 31088831, 25169980, 27870574, 23082000, 31340094, 30745300	Brichory F et al. Abstract# 2088, AACR 2017 http://cancerres.aacrjournals.org/content/77/13_Supplement/2088
ENST00000358487	NM_000141.4	2263	FGFR2	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	AZD4547, BGJ398, Erdafitinib, Debio1347	26438159, 31088831, 25169980, 27870574, 23082000, 31340094, 30745300	Brichory F et al. Abstract# 2088, AACR 2017 http://cancerres.aacrjournals.org/content/77/13_Supplement/2088
ENST00000260795	NM_000142.4	2261	FGFR3	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	AZD4547, Erdafitinib, BGJ398, Debio1347	26438159, 21119661, 31088831, 29848605, 26324363, 25169980, 27870574, 23082000, 31340094, 30745300	Siefker-Radtke et al. Abstract#4503, ASCO 2018 https://meetinglibrary.asco.org/record/160559/abstract; Brichory F et al. Abstract# 2088, AACR 2017 http://cancerres.aacrjournals.org/content/77/13_Supplement/2088
ENST00000527786	NM_002017.4	2313	FLI1	EWSR1-FLI1 Fusion	EWSR1-FLI1 Fusion	Ewing Sarcoma	4	TK216	19584866	Selvanathan et al. Abstract# 694, AACR 2017 http://cancerres.aacrjournals.org/content/77/13_Supplement/694
ENST00000527786	NM_002017.4	2313	FLI1	EWSR1-FLI1 Fusion	EWSR1-FLI1 Fusion	Ewing Sarcoma of Soft Tissue	4	TK216	19584866	Selvanathan et al. Abstract# 694, AACR 2017 http://cancerres.aacrjournals.org/content/77/13_Supplement/694
ENST00000377967	NM_021140.2	7403	KDM6A	Oncogenic Mutations	Oncogenic Mutations	Bladder Cancer	4	Tazemetostat	24123378, 28228601, 29045832, 29059780	
ENST00000256078	NM_033360.2	3845	KRAS	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	Cobimetinib, Binimetinib, Trametinib	29247021, 28783719	Robarge et al. Abstract# DDT02-03, AACR 2014 http://cancerres.aacrjournals.org/content/74/19_Supplement/DDT02-03; Bhagwat et al. Abstract# 4973, AACR 2017 http://cancerres.aacrjournals.org/content/77/13_Supplement/4973; Burrows et al. Abstract# 5168, AACR 2017 http://cancerres.aacrjournals.org/content/77/13_Supplement/5168
ENST00000397752	NM_000245.2	4233	MET	Fusions	Fusions	All Solid Tumors	4	Crizotinib	29102694, 29527595, 29284707	Wang et al. Abstract#e13539, ASCO 2018 http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539; Arguello et al. Abstract#P2.08, IASLC 2016 https://www.jto.org/article/S1556-0864(16
ENST00000361445	NM_004958.3	2475	MTOR	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	Temsirolimus, Everolimus	24631838, 27482884, 30327302, 26831717, 24622468	
ENST00000358273	NM_001042492.2	4763	NF1	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	Cobimetinib, Trametinib	24576830, 26936308, 24535670	
ENST00000371953	NM_000314.4	5728	PTEN	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	GSK2636771, AZD8186	28645941	Hansen et al. Abstract# 2570, ASCO 2017 http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2570
ENST00000335508	NM_012433.2	23451	SF3B1	Oncogenic Mutations	Oncogenic Mutations	Acute Myeloid Leukemia	4	H3B-8800	29457796	Buonamici, S. et al. Abstract# Blood 128:966, 2016 http://www.bloodjournal.org/content/128/22/966?sso-checked=true
ENST00000335508	NM_012433.2	23451	SF3B1	Oncogenic Mutations	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	4	H3B-8800	29457796	Buonamici, S. et al. Abstract# Blood 128:966, 2016 http://www.bloodjournal.org/content/128/22/966?sso-checked=true
ENST00000335508	NM_012433.2	23451	SF3B1	Oncogenic Mutations	Oncogenic Mutations	Myelodysplastic Syndromes	4	H3B-8800	29457796	Buonamici, S. et al. Abstract# Blood 128:966, 2016 http://www.bloodjournal.org/content/128/22/966?sso-checked=true
ENST00000263121	NM_003073.3	6598	SMARCB1	Oncogenic Mutations	Oncogenic Mutations	All Tumors	4	Tazemetostat	29650362, 23620515, 20951942, 27391784	Chi et al. Abstract# A175, AACR-NCI-EORTC 2017 http://www.abstractsonline.com/pp8/#!/4557/presentation/616
ENST00000359995	NM_003016.4	6427	SRSF2	Oncogenic Mutations	Oncogenic Mutations	Acute Myeloid Leukemia	4	H3B-8800	29457796	Buonamici, S. et al. Abstract# Blood 128:966, 2016 http://www.bloodjournal.org/content/128/22/966?sso-checked=true
ENST00000359995	NM_003016.4	6427	SRSF2	Oncogenic Mutations	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	4	H3B-8800	29457796	Buonamici, S. et al. Abstract# Blood 128:966, 2016 http://www.bloodjournal.org/content/128/22/966?sso-checked=true
ENST00000359995	NM_003016.4	6427	SRSF2	Oncogenic Mutations	Oncogenic Mutations	Myelodysplastic Syndromes	4	H3B-8800	29457796	Buonamici, S. et al. Abstract# Blood 128:966, 2016 http://www.bloodjournal.org/content/128/22/966?sso-checked=true
ENST00000291552	NM_006758.2	7307	U2AF1	Oncogenic Mutations	Oncogenic Mutations	Acute Myeloid Leukemia	4	H3B-8800	29457796	Buonamici, S. et al. Abstract# Blood 128:966, 2016 http://www.bloodjournal.org/content/128/22/966?sso-checked=true
ENST00000291552	NM_006758.2	7307	U2AF1	Oncogenic Mutations	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	4	H3B-8800	29457796	Buonamici, S. et al. Abstract# Blood 128:966, 2016 http://www.bloodjournal.org/content/128/22/966?sso-checked=true
ENST00000291552	NM_006758.2	7307	U2AF1	Oncogenic Mutations	Oncogenic Mutations	Myelodysplastic Syndromes	4	H3B-8800	29457796	Buonamici, S. et al. Abstract# Blood 128:966, 2016 http://www.bloodjournal.org/content/128/22/966?sso-checked=true
ENST00000307771	NM_005089.3	8233	ZRSR2	Oncogenic Mutations	Oncogenic Mutations	Acute Myeloid Leukemia	4	H3B-8800	29457796	Buonamici, S. et al. Abstract# Blood 128:966, 2016 http://www.bloodjournal.org/content/128/22/966?sso-checked=true
ENST00000307771	NM_005089.3	8233	ZRSR2	Oncogenic Mutations	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	4	H3B-8800	29457796	Buonamici, S. et al. Abstract# Blood 128:966, 2016 http://www.bloodjournal.org/content/128/22/966?sso-checked=true
ENST00000307771	NM_005089.3	8233	ZRSR2	Oncogenic Mutations	Oncogenic Mutations	Myelodysplastic Syndromes	4	H3B-8800	29457796	Buonamici, S. et al. Abstract# Blood 128:966, 2016 http://www.bloodjournal.org/content/128/22/966?sso-checked=true
ENST00000389048	NM_004304.4	238	ALK	C1156Y	C1156Y	Non-Small Cell Lung Cancer	R2	Crizotinib	22235099, 23434628, 27045755, 26144315, 20979473, 26698910, 24675041	
ENST00000389048	NM_004304.4	238	ALK	G1202R	G1202R	Non-Small Cell Lung Cancer	R2	Alectinib	29376144, 29650534, 27130468, 27432227, 24736079, 29373100	
ENST00000389048	NM_004304.4	238	ALK	G1269A	G1269A	Non-Small Cell Lung Cancer	R2	Crizotinib	28434515, 22235099, 23434628, 27045755, 23344087, 24675041	
ENST00000389048	NM_004304.4	238	ALK	I1171N	I1171N	Non-Small Cell Lung Cancer	R2	Alectinib	29376144, 23239810, 29650534, 25393798, 25393796, 27565911, 25736571	
ENST00000389048	NM_004304.4	238	ALK	L1196M	L1196M	Non-Small Cell Lung Cancer	R2	Crizotinib	28434515, 22235099, 23434628, 22277784, 23344087, 27432227, 24675041	
ENST00000275493	NM_005228.3	1956	EGFR	C797G	C797G	Non-Small Cell Lung Cancer	R2	Osimertinib	29713646, 27086175	
ENST00000275493	NM_005228.3	1956	EGFR	C797S	C797S	Non-Small Cell Lung Cancer	R2	Osimertinib	26749488, 28625641, 26181354, 25939061	
ENST00000275493	NM_005228.3	1956	EGFR	D761Y	D761Y	Non-Small Cell Lung Cancer	R2	Gefitinib	28424065, 17085664, 17192902, 22052230	
ENST00000288135	NM_000222.2	3815	KIT	Exon 17 mutations	C788_N828mut	Gastrointestinal Stromal Tumor	R2	Imatinib, Sunitinib	22301675, 23840364, 25239608, 18955458	
ENST00000288135	NM_000222.2	3815	KIT	T670I	T670I	Gastrointestinal Stromal Tumor	R2	Imatinib	16551858, 17545544, 23840364, 1675110, 16954519, 17699867	
ENST00000288135	NM_000222.2	3815	KIT	V654A	V654A	Gastrointestinal Stromal Tumor	R2	Imatinib	16551858, 23840364, 18955458, 16954519	
ENST00000397752	NM_000245.2	4233	MET	Amplification	Amplification	Non-Small Cell Lung Cancer	R2	Erlotinib, Osimertinib, Gefitinib	30073261, 30676858, 18093943, 17463250	Michels et al. JCO PO, 2018 https://ascopubs.org/doi/full/10.1200/PO.18.00210
ENST00000397752	NM_000245.2	4233	MET	D1228N	D1228N	Non-Small Cell Lung Cancer	R2	Crizotinib, Cabozantinib, Capmatinib	28396313, 27987579, 28522754, 27343442, 29128427	
ENST00000397752	NM_000245.2	4233	MET	Y1230H	Y1230H	Non-Small Cell Lung Cancer	R2	Crizotinib, Capmatinib	27666659, 28396313, 27987579, 28522754, 29128427	
ENST00000524377	NM_002529.3	4914	NTRK1	G595R	G595R	All Solid Tumors	R2	Larotrectinib	29466156	
ENST00000360948	NM_001012338.2	4916	NTRK3	G623R	G623R	All Solid Tumors	R2	Larotrectinib	29466156, 28578312	
